An interventional study of 18F-PET-TT in Chronic Kidney Disease, sponsored by Turku University Hospital. Status unknown at 1 site in Finland. Open to participants aged 25 Years to 95 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-05-13.
Sponsored by Turku University Hospital · Not applicable, Interventional, and Diagnostic
Chronic kidney disease (CKD) is an increasing public health problem and the number of patient with chronic kidney disease is increasing worldwide. Bone abnormalities are found almost universally in patients with CKD requiring dialysis and in the majority of patients with CKD stages 3-5. Chronic kidney disease-mineral bone disorder (CKD-MBD) is a complex disorder of bone and mineral metabolism, which is associated with disorder in circulating levels of hormones and development of secondary hyperparathyroid disease. The abnormalities of mineral homeostasis impair bone remodeling and mineralization and results in cortical and trabecular defects and an increased fracture risk. There is also an association with increased morbidity and mortality. CKD-MBD is also associated with development of calcification of the blood vessels. During the last decade it has been increasingly acknowledged that mineral and bone disorder contribute to the excessively high cardiovascular morbidity and mortality in patients with chronic kidney disease.
The diagnosis of mineral bone disorder and the underlying bone histology in CKD patients is challenging. The treatment of renal osteodystrophy (ROD) and especially the treatment of fractures in this patient group, depends on the underlying bone histopathology and bone turnover. The gold standard for diagnosing the subtypes of ROD is bone biopsy, but it is invasive and requires considerable expertise regarding quantitative histomorphometry and interpretation. Plasma parathormone (PTH) measurement is commonly used to evaluate these patients, and generally extremely high or low PTH levels predict the underlying bone disorder. Still PTHs ability to correctly estimate turnover in bone is limited. Several biomarkers such as tartrate-resistant acid phosphatase 5b (TRAP5b) and procollagen type 1 N-terminal propetide (PINP) has been investigated, but no biomarker in clinical use has yet been proven suitable or superior to PTH to estimate overall bone histology.
18F-NaF positron emission tomography (18F-NaF PET) is a noninvasive quantitative imaging technique that allows assessment of regional bone turnover at clinically relevant sites. 18F-NaF is a bone-seeking tracer, which reflects remodeling of bone and osteoblast activity25. 18F-NaF serves as an efficient tracer to measure metabolic changes in bone. A correlation between histomorphometric markers such as bone formation rate (BFR) and tracer activity in the 18F- NaF PET scan in CKD patients has previously been shown in one small study.
This study's goal is to evaluate, if 18-NaF-Positron emission tomography-computed tomography (18F-PET-TT) can be used in the assessment of CKD patients. The hypothesis is that 18F-PET-TT correlates with the histomorphometry of bone biopsy and with the calcification score in CKD patients and that 18F-PET-TT maybe can be used as a diagnostic imaging technique in the future.
This is a cross-sectional prospective study. 10 - 20 patients with secondary/tertiary hyprparathyreoidism on oeritoneal dialysis, hemodialysis, predialysis patients and patients, who have received a kidney transplant will be included,. Data collection in the dialysis group is finnished and the first article published (Aaltonen et al, Bone 2020). A control group was recruited for validation of the PET-method.
All participants undergo a 18F-PET-TT scan. PET, with the short half-life bone seeking 18F-Sodium Fluoride (18F-NaF), provide an unique way of assessment of regional bone metabolism. 18F-NaF binds to sights of new bone formation and serves as a marker of bone blood flow and osteoblastic activity. A dynamic 18F-PET-TT imaging is first done of the lumbar region of the spine, following with a static PET-TT and also measurement of calcification score using PET-TT. 18F-NaF is injected intravenously by direct venipuncture or intravenous catheter. All the patients are also asked for permission to use DNA-samples if needed.
Blood tests measuring the bone formation and turnover will be taken during the normal clinical controls of the patients or at the latest wheb the bone biopsy is takekn. Echocardiogram, which is reasonable sensitive, is done to detect and evaluate valvular calcification. Bone biopsy is done in the day care unit within one month from the PET-scan. To obtain information about dynamic parameters of the bone, the patients had double labeling with tetracycline. The biopsy is taken in local anesthesia from the anterior iliac spine vertically.
3,224 studies on the registry are indexed under Renal Insufficiency, Chronic; 706 are open to participants now.
This study's planned enrollment of 90 is above the median of 74 across 2,229 interventional studies indexed under Renal Insufficiency, Chronic.
Browse Renal Insufficiency, Chronic studies →Turku University Hospital is the lead sponsor of 286 studies on the registry; 66 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Device: 18F-PET-TT
can 18F-PET-TT be used as an diagnostic tool in patients with CKD-MBD
Evidence of kidney patients adynamic or hyperdynamic bone disease assessed by 18F-PET-TT
18F-PET correlates with histomorphometric markers in bone biopsy
Time frame: 3 years
Plan to share: No
Started Dec 2016 (actual). Primary completion is estimated for Dec 2021, 60 months after the start.
Of 579 non-industry interventional studies with no phase under Renal Insufficiency, Chronic, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 44. This study's planned 60 months is above that.
Counting every sponsor, half of 617 studies reached it within 23 months; a quarter within 10 and three quarters within 44.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in May 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Renal Insufficiency, Chronic →